Logo Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Vertex Pharmaceuticals · Health Care · ref. ETF XLV · 99 calls · price $547.55
🔔Price alertsCreate an alert →
What the company does: Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

📈 Vertex Pharmaceuticals (VRTX) stock price

$547.55+39.7% over range
Aug 28, 25low $376.62 · high $552.85Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
88% recommend buying · 16 analysts
📊 JPI status : Vertex Pharmaceuticals is no longer in our current JPI rankings, but appeared in the past (2017) — its upside may be behind it. See the stocks picked in 2017 →

🎯 VRTX price target & analyst consensusprice $548

The price target · all analysts combined (16 targets)
Highest target · 1 firm of 16$641+17.1%
Median target · of 16 targets$582.5+6.4%
Lowest target · 1 firm of 16$350-36.1%
Current price$547.55
Where these 16 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 1488% $550 ↔ $641
Below 213% $350 ↔ $442
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS66% of its targets hit on this sector (355 calls tested). It aims for $585 (+6.8 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).

The 6 reliable analysts $558+1.8 %
The 10 other firms $590+7.8 %
How to read it: the 6 reliable firms are not filtered by optimism — 4 aim above the price, 2 below, hence their $558 median. “The 10 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 16 ratings (last 6 months)
Strong Buy00%
Buy1488%
Hold16%
Sell16%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Vertex Pharmaceuticals? The JPI assistant answers using our backtest data.

📈 Vertex Pharmaceuticals fundamentals: valuation, margins & growth › open the full page

P/E 31.9Net margin 35.0 %Revenue growth +12.5 %High P/E

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 37 %
2023
Rev +11%Profit +9%
2024
Rev +12%Profit −115%
2025
Rev +9%

🔎 Detailed analyses

✅ Historical analyst reliability on VRTX

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Janney Montgomery Scott 100% +37.7% 2
Baird  100% +33.8% 8
Evercore ISI Group  100% +29.9% 10
Cowen & Co. 100% +26.1% 2
William Blair  100% +23.1% 2
Maxim Group 100% +14.8% 3
Raymond James  100% +13.6% 2
Piper Sandler  90% +16.7% 10
Wells Fargo  89% +24.2% 9
BMO Capital  86% +20.6% 14
See the other 26 firms
Canaccord Genuity  33% -9.8% 6
SunTrust Robinson Humphrey 50% -13.9% 2
CFRA 50% -7.0% 2
Stifel  50% -0.3% 8
SVB Leerink 50% +0.5% 4
Citigroup  50% +6.3% 14
Morgan Stanley  54% +3.8% 13
Argus Research  57% +11.0% 7
Credit Suisse 58% +12.6% 12
JMP Securities 60% +15.7% 5
Cantor Fitzgerald  63% +11.8% 30
Leerink Swann 67% -6.1% 3
B of A Securities  67% +12.2% 12
Jefferies  67% +31.5% 6
JP Morgan  69% +8.9% 13
Goldman Sachs  71% +10.0% 7
Guggenheim  71% +17.3% 7
RBC Capital  73% +17.3% 15
Barclays  74% +14.8% 19
UBS  74% +18.4% 19
Oppenheimer  75% +12.3% 12
HC Wainwright & Co.  77% +15.8% 26
Truist Securities  80% +14.0% 10
TD Cowen  80% +20.4% 5
Bernstein  80% +23.7% 5
Deutsche Bank  83% +29.0% 6

📊 What $1,000 invested in Vertex Pharmaceuticals would be worth › open the full page

In short — $1,000 invested in Vertex Pharmaceuticals 10 years ago would be worth $3,948 today, i.e. +15%/yr on average. Best year: 2017 (+103%), worst: 2016 (-41%). Price performance, excluding dividends.

If I'd invested $1,000 in Vertex Pharmaceuticals

InvestmentWorth todayGain
1 years ago$1,233+23%
3 years ago$1,720+72%
5 years ago$2,102+110%
→ See Vertex Pharmaceuticals's full return history + gain calculator

Return by year (Vertex Pharmaceuticals)

YearReturn$1,000 invested at year start
2026 (YTD)+10%$1,096 (+10%)
2025+13%$1,233 (+23%)
2024-1%$1,221 (+22%)
→ See Vertex Pharmaceuticals's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Vertex Pharmaceuticals

Loading news…

📋 All analyst calls on VRTX

▲ Buy · 🎯$565
Price at call : $484.03 — upside +17%
Today : $547.55 — upside +3%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Aug 5, 27
Barclays 
Aug 5, 26
▲ Overweight · 🎯$617
Price at call : $484.03 — upside +27%
Today : $547.55 — upside +13%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 5, 27
TD Cowen 
Aug 4, 26
▲ Buy · 🎯$550
Price at call : $484.83 — upside +13%
Today : $547.55 — upside +0%
🎯 on VRTX : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Aug 4, 27
▲ Overweight · 🎯$595
Price at call : $478.71 — upside +24%
Today : $547.55 — upside +9%
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Aug 4, 27
■ Hold neutral · not a buy · 🎯$442
Price at call : $478.71 — gap to target -8%
Today : $547.55 — gap to target -19%
🎯 on VRTX : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Aug 4, 27
UBS 
Jul 13, 26
▲ Buy · 🎯$585
Price at call : $476.31 — upside +23%
Today : $547.55 — upside +7%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 13, 27
▲ Buy · 🎯$560
Price at call : $476.31 — upside +18%
Today : $547.55 — upside +2%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 13, 27
RBC Capital 
Jul 7, 26
▲ Outperform · 🎯$570
Price at call : $498.43 — upside +14%
Today : $547.55 — upside +4%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 7, 27
See the other 91 calls, newest to oldest
Baird 
Jul 7, 26
▼ Underperform · 🎯$350
Price at call : $522.25 — upside -33%
Today : $547.55 — upside -36%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Jul 7, 27
Barclays 
May 6, 26
▲ Overweight · 🎯$615
Price at call : $425 — upside +45%
Today : $547.55 — upside +12%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 6, 27
■ Hold neutral · not a buy · 🎯$436
Price at call : $427.65 — gap to target +2%
Today : $547.55 — gap to target -20%
🎯 on VRTX : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : May 5, 27
▲ Overweight · 🎯$616
Price at call : $427.65 — upside +44%
Today : $547.55 — upside +13%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : May 5, 27
Bernstein 
May 5, 26
▲ Outperform · 🎯$572
Price at call : $427.65 — upside +34%
Today : $547.55 — upside +4%
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : May 5, 27
RBC Capital 
May 5, 26
▲ Outperform · 🎯$543
Price at call : $427.65 — upside +27%
Today : $547.55 — upside -1%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 5, 27
■ Hold neutral · not a buy · 🎯$437
Price at call : $423.92 — gap to target +3%
Today : $547.55 — gap to target -20%
🎯 on VRTX : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : May 1, 27
Morgan Stanley 
Apr 10, 26
▲ Overweight · 🎯$612
Price at call : $440.05 — upside +39%
Today : $547.55 — upside +12%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
Maxim Group
Mar 18, 26
▲ Buy · 🎯$575
Price at call : $458.05 — upside +26%
Today : $547.55 — upside +5%
🎯 on VRTX : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Mar 18, 27
▲ Buy · 🎯$525
Price at call : $478.13 — upside +10%
Today : $547.55 — upside -4%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Mar 11, 27
Morgan Stanley 
Mar 10, 26
▲ Overweight · 🎯$596
Price at call : $492.38 — upside +21%
Today : $547.55 — upside +9%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Mar 10, 27
▲ Buy · 🎯$598
Price at call : $492.38 — upside +21%
Today : $547.55 — upside +9%
🎯 on VRTX : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Mar 10, 27
Citigroup 
Mar 10, 26
▲ Buy · 🎯$585
Price at call : $492.38 — upside +19%
Today : $547.55 — upside +7%
🎯 on VRTX : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 10, 27
Oppenheimer 
Mar 10, 26
▲ Outperform · 🎯$600
Price at call : $492.38 — upside +22%
Today : $547.55 — upside +10%
🎯 on VRTX : no call matured yet · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Mar 10, 27
Jefferies 
Mar 10, 26
▲ Buy · 🎯$580
Price at call : $492.38 — upside +18%
Today : $547.55 — upside +6%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Mar 10, 27
▲ Buy · 🎯$641
Price at call : $499.17 — upside +28%
Today : $547.55 — upside +17%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Mar 10, 27
■ Hold neutral · not a buy · 🎯$441
Price at call : $470.31 — gap to target -6%
Today : $547.55 — gap to target -19%
🎯 on VRTX : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Feb 17, 27
Barclays 
Feb 17, 26
▲ Overweight · 🎯$607
Price at call : $470.31 — upside +29%
Today : $547.55 — upside +11%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 17, 27
▲ Buy · 🎯$591
Price at call : $477.32 — upside +24%
Today : $547.55 — upside +8%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 17, 27
Scotiabank 
Feb 13, 26
■ Sector Perform neutral · not a buy · 🎯$558
Price at call : $477.32 — gap to target +17%
Today : $547.55 — gap to target +2%
🎯 on VRTX : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Feb 13, 27
RBC Capital 
Feb 13, 26
▲ Outperform · 🎯$541
Price at call : $477.32 — upside +13%
Today : $547.55 — upside -1%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 13, 27
Stifel 
Feb 13, 26
■ Hold neutral · not a buy · 🎯$466
Price at call : $477.32 — gap to target -2%
Today : $547.55 — gap to target -15%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Feb 13, 27
Oppenheimer 
Feb 13, 26
▲ Outperform · 🎯$540
Price at call : $477.32 — upside +13%
Today : $547.55 — upside -1%
🎯 on VRTX : no call matured yet · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Feb 13, 27
▲ Buy · 🎯$518
Price at call : $491.47 — upside +5%
Today : $547.55 — upside -5%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 13, 27
Barclays 
Jan 28, 26
▲ Overweight · 🎯$606
Price at call : $475.68 — upside +27%
Today : $547.55 — upside +11%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jan 28, 27
UBS 
Jan 26, 26
▲ Buy · 🎯$545
Price at call : $474.17 — upside +15%
Today : $547.55 — upside -0%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jan 26, 27
▲ Outperform · 🎯$530
Price at call : $468.41 — upside +13%
Today : $547.55 — upside -3%
🎯 on VRTX : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Jan 23, 27
RBC Capital 
Jan 22, 26
▲ Outperform · 🎯$546
Price at call : $468.41 — upside +17%
Today : $547.55 — upside -0%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jan 22, 27
Bernstein 
Jan 12, 26
▲ Outperform
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Jan 12, 27
▲ Outperform · 🎯$548
Price at call : $468.38 — upside +17%
Today : $547.55 — upside +0%
🎯 on VRTX : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Jan 6, 27
▲ Outperform · 🎯$525
Price at call : $459.78 — upside +14%
Today : $547.55 — upside -4%
🎯 on VRTX : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Dec 29, 26
Wells Fargo 
Dec 10, 25
▲ Overweight · 🎯$515
Price at call : $445.93 — upside +15%
Today : $547.55 — upside -6%
🎯 on VRTX : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 10, 26
▲ Overweight · 🎯$564
Price at call : $442.04 — upside +28%
Today : $547.55 — upside +3%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 5, 26
▲ Overweight · 🎯$516
Price at call : $457.36 — upside +13%
Today : $547.55 — upside -6%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 3, 26
UBS 
Nov 7, 25
▲ Buy · 🎯$546
Price at call : $421.2 — upside +30%
Today : $547.55 — upside -0%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Nov 7, 26
RBC Capital 
Nov 4, 25
■ Sector Perform neutral · not a buy · 🎯$415
Price at call : $417 — gap to target -0%
Today : $547.55 — gap to target -24%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Nov 4, 26
Barclays 
Nov 4, 25
■ Equal-Weight neutral · not a buy · 🎯$414
Price at call : $421.67 — gap to target -2%
Today : $547.55 — gap to target -24%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Nov 4, 26
Stifel 
Nov 4, 25
■ Hold neutral · not a buy · 🎯$445
Price at call : $421.67 — gap to target +6%
Today : $547.55 — gap to target -19%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Nov 4, 26
Morgan Stanley 
Oct 10, 25
■ Equal-Weight neutral · not a buy · 🎯$438
Price at call : $407.37 — gap to target +8%
Today : $547.55 — gap to target -20%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 10, 26
JP Morgan 
Oct 8, 25
▲ Overweight · 🎯$530
Price at call : $414.86 — upside +28%
Today : $547.55 — upside -3%
🎯 on VRTX : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Oct 8, 26
Citigroup 
Oct 2, 25
▲ Buy · 🎯$575
Price at call : $403.3 — upside +43%
Today : $547.55 — upside +5%
🎯 on VRTX : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Oct 2, 26
▲ Outperform · 🎯$456
Price at call : $381.87 — upside +19%
Today : $547.55 — upside -17%
🎯 on VRTX : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Sep 25, 26
UBS 
Aug 5, 25
▲ Buy · 🎯$553
Price at call : $385.65 — upside +43%
Today : $547.55 — upside +1%
Expected +43% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+25.5%
stock +26% · XLV +26%
matured Aug 5, 26
▲ Overweight · 🎯$485
Price at call : $374.98 — upside +29%
Today : $547.55 — upside -11%
Expected +29% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+29.3%
stock +29% · XLV +24%
matured Aug 5, 26
▲ Buy · 🎯$478
Price at call : $374.98 — upside +27%
Today : $547.55 — upside -13%
Expected +27% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+29.3%
stock +29% · XLV +24%
matured Aug 5, 26
▲ Buy · 🎯$550
Price at call : $443.54 — upside +24%
Today : $547.55 — upside +0%
Expected +24% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+5.6%
stock +6% · XLV +15%
matured Jun 23, 26
▲ Overweight · 🎯$535
Price at call : $450.03 — upside +19%
Today : $547.55 — upside -2%
Expected +19% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-5.0%
stock -5% · XLV +8%
matured May 6, 26
■ Market Perform neutral · not a buy · 🎯$503
Price at call : $450.03 — gap to target +12%
Today : $547.55 — gap to target -8%
🎯 on VRTX : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : May 6, 26
UBS 
Feb 11, 25
▲ Buy · 🎯$583
Price at call : $453.2 — upside +29%
Today : $547.55 — upside +6%
Expected +29% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+2.6%
stock +3% · XLV +7%
matured Feb 11, 26
▲ Overweight · 🎯$480
Price at call : $453.2 — upside +6%
Today : $547.55 — upside -12%
Expected +6% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+2.6%
stock +3% · XLV +7%
matured Feb 11, 26
▲ Buy · 🎯$550
Price at call : $455.22 — upside +21%
Today : $547.55 — upside +0%
Expected +21% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+1.3%
stock +1% · XLV +7%
matured Feb 11, 26
▲ Overweight · 🎯$480
Price at call : $470.37 — upside +2%
Today : $547.55 — upside -12%
Expected +2% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+0.4%
stock +0% · XLV +6%
matured Jan 31, 26
▲ Buy · 🎯$550
Price at call : $461.68 — upside +19%
Today : $547.55 — upside +0%
Expected +19% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+2.2%
stock +2% · XLV +6%
matured Jan 31, 26
▲ Overweight · 🎯$480
Price at call : $443.88 — upside +8%
Today : $547.55 — upside -12%
Expected +8% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+7.4%
stock +7% · XLV +7%
matured Jan 24, 26
▲ Buy · 🎯$535
Price at call : $397.27 — upside +35%
Today : $547.55 — upside -2%
Expected +35% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+15.9%
stock +16% · XLV +13%
matured Dec 20, 25
UBS 
Nov 5, 24
▲ Buy · 🎯$586
Price at call : $493.64 — upside +19%
Today : $547.55 — upside +7%
Expected +19% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
-15.7%
stock -16% · XLV -1%
matured Nov 5, 25
▲ Overweight · 🎯$480
Price at call : $493.64 — upside -3%
Today : $547.55 — upside -12%
Expected -3% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-15.7%
stock -16% · XLV -1%
matured Nov 5, 25
▲ Buy · 🎯$600
Price at call : $478.09 — upside +25%
Today : $547.55 — upside +10%
Expected +25% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-10.8%
stock -11% · XLV -4%
matured Oct 21, 25
UBS 
Oct 17, 24
▲ Buy · 🎯$562
Price at call : $483 — upside +16%
Today : $547.55 — upside +3%
Expected +16% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
-13.2%
stock -13% · XLV -5%
matured Oct 17, 25
▲ Overweight · 🎯$480
Price at call : $467.97 — upside +3%
Today : $547.55 — upside -12%
Expected +3% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-11.3%
stock -11% · XLV -6%
matured Oct 8, 25
▲ Buy · 🎯$600
Price at call : $474.29 — upside +27%
Today : $547.55 — upside +10%
Expected +27% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-18.7%
stock -19% · XLV -12%
matured Aug 5, 25
▲ Overweight · 🎯$480
Price at call : $476.91 — upside +1%
Today : $547.55 — upside -12%
Expected +1% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-1.0%
stock -1% · XLV -9%
matured Aug 2, 25
▲ Overweight · 🎯$480
Price at call : $490.32 — upside -2%
Today : $547.55 — upside -12%
Expected -2% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-2.7%
stock -3% · XLV -8%
matured Jul 22, 25
▲ Buy · 🎯$500
Price at call : $491.57 — upside +2%
Today : $547.55 — upside -9%
Expected +2% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-6.7%
stock -7% · XLV -11%
matured Jul 19, 25
Argus Research 
Jun 17, 24
▲ Buy · 🎯$550
Price at call : $467.28 — upside +18%
Today : $547.55 — upside +0%
Expected +18% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-4.0%
stock -4% · XLV -9%
matured Jun 17, 25
▲ Buy · 🎯$462
Price at call : $410.24 — upside +13%
Today : $547.55 — upside -16%
Expected +13% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+6.0%
stock +6% · XLV -5%
matured May 7, 25
UBS 
Apr 17, 24
▲ Buy · 🎯$466
Price at call : $393.1 — upside +19%
Today : $547.55 — upside -15%
Expected +19% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+24.4%
stock +24% · XLV -2%
matured Apr 17, 25
▲ Buy · 🎯$462
Price at call : $400.23 — upside +15%
Today : $547.55 — upside -16%
Expected +15% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+21.0%
stock +21% · XLV -3%
matured Apr 11, 25
▲ Overweight · 🎯$440
Price at call : $419.63 — upside +5%
Today : $547.55 — upside -20%
Expected +5% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+14.5%
stock +14% · XLV +1%
matured Feb 19, 25
▲ Overweight · 🎯$440
Price at call : $419.08 — upside +5%
Today : $547.55 — upside -20%
Expected +5% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+14.8%
stock +15% · XLV +2%
matured Feb 5, 25
▲ Buy · 🎯$457
Price at call : $416.13 — upside +10%
Today : $547.55 — upside -17%
Expected +10% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+17.4%
stock +17% · XLV +3%
matured Feb 5, 25
▲ Overweight · 🎯$440
Price at call : $429.96 — upside +2%
Today : $547.55 — upside -20%
Expected +2% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+2.3%
stock +2% · XLV +4%
matured Jan 23, 25
▲ Buy · 🎯$397
Price at call : $356.29 — upside +11%
Today : $547.55 — upside -27%
Expected +11% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+31.7%
stock +32% · XLV +8%
matured Dec 10, 24
Bernstein 
Aug 2, 23
▲ Outperform · 🎯$390
Price at call : $358.4 — upside +9%
Today : $547.55 — upside -29%
Expected +9% · Actual +41% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
+41.1%
stock +41% · XLV +13%
matured Aug 1, 24
Bernstein 
Jul 28, 23
▲ Outperform · 🎯$380
Price at call : $352.34 — upside +8%
Today : $547.55 — upside -31%
Expected +8% · Actual +41% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
+41.4%
stock +41% · XLV +12%
matured Jul 27, 24
UBS 
Jul 24, 23
▲ Buy · 🎯$424
Price at call : $358.06 — upside +18%
Today : $547.55 — upside -23%
Expected +18% · Actual +37% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+37.1%
stock +37% · XLV +10%
matured Jul 23, 24
Bernstein 
May 3, 23
▲ Outperform · 🎯$363
Price at call : $346.36 — upside +5%
Today : $547.55 — upside -34%
Expected +5% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
+15.5%
stock +16% · XLV +5%
matured May 2, 24
UBS 
May 2, 23
▲ Buy · 🎯$399
Price at call : $346.36 — upside +15%
Today : $547.55 — upside -27%
Expected +15% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+15.5%
stock +16% · XLV +5%
matured May 1, 24
Argus Research 
Mar 29, 23
▲ Buy · 🎯$350
Price at call : $312.16 — upside +12%
Today : $547.55 — upside -36%
Expected +12% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+34.7%
stock +35% · XLV +14%
matured Mar 28, 24
Bernstein 
Mar 21, 23
▲ Outperform · 🎯$344
Price at call : $302.66 — upside +14%
Today : $547.55 — upside -37%
Expected +14% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
+36.2%
stock +36% · XLV +14%
matured Mar 20, 24
UBS 
Feb 8, 23
▲ Buy · 🎯$375
Price at call : $291.6 — upside +29%
Today : $547.55 — upside -32%
Expected +29% · Actual +45% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+45.0%
stock +45% · XLV +10%
matured Feb 8, 24
UBS 
Jan 30, 23
▲ Buy · 🎯$373
Price at call : $323.1 — upside +15%
Today : $547.55 — upside -32%
Expected +15% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+34.1%
stock +34% · XLV +5%
matured Jan 30, 24
Argus Research 
Nov 17, 22
▲ Buy · 🎯$340
Price at call : $314.63 — upside +8%
Today : $547.55 — upside -38%
Expected +8% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+13.4%
stock +13% · XLV -4%
matured Nov 17, 23
UBS 
Oct 21, 22
▲ Buy · 🎯$337
Price at call : $310.5 — upside +9%
Today : $547.55 — upside -38%
Expected +9% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+18.4%
stock +18% · XLV -1%
matured Oct 21, 23
Argus Research 
Jun 13, 22
▲ Buy · 🎯$280
Price at call : $245.39 — upside +14%
Today : $547.55 — upside -49%
Expected +14% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+39.4%
stock +39% · XLV +8%
matured Jun 13, 23
UBS 
Apr 27, 22
▲ Buy · 🎯$322
Price at call : $268.64 — upside +20%
Today : $547.55 — upside -41%
Expected +20% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+26.8%
stock +27% · XLV -0%
matured Apr 27, 23
UBS 
Apr 13, 22
▲ Buy · 🎯$325
Price at call : $287.97 — upside +13%
Today : $547.55 — upside -41%
Expected +13% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+15.8%
stock +16% · XLV -3%
matured Apr 13, 23
Bernstein 
Nov 20, 20
▲ Outperform · 🎯$275
Price at call : $215.21 — upside +28%
Today : $547.55 — upside -50%
Expected +28% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 80% (5 calls matureds) · 📊 on Health : 54.7% · +5.2% (64 calls)
-15.7%
stock -16% · XLV +22%
matured Nov 20, 21
Argus Research 
May 15, 20
▲ Buy · 🎯$320
Price at call : $284.13 — upside +13%
Today : $547.55 — upside -42%
Expected +13% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-23.9%
stock -24% · XLV +22%
matured May 15, 21
Argus Research 
Sep 28, 15
▲ Buy
Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-9.5%
stock -10% · XLV +13%
matured Sep 27, 16
▲ Buy
Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+27.0%
stock +27% · XLV +23%
matured Oct 4, 13

Frequently asked questions

Should I buy Vertex Pharmaceuticals stock?

This isn't buy advice. For Vertex Pharmaceuticals, the analyst consensus is "Buy", with an average price target of $583 (+6% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Vertex Pharmaceuticals). We show the numbers — you decide.

Is it too late to buy Vertex Pharmaceuticals? How high can it go?

The most bullish analyst target on Vertex Pharmaceuticals is $641 (+17% above today's price); the average is $583. That's the upside they see. Check how reliable those analysts have actually been on Vertex Pharmaceuticals on our site before trusting it.

Is Vertex Pharmaceuticals still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 36 analysts have a real record on Vertex Pharmaceuticals, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Vertex Pharmaceuticals? The case for and against

The arguments for and against, one by one, from the numbers: why invest in VRTX (and why hesitate).

What has Vertex Pharmaceuticals's past performance been?

Historical returns and a "how much if I had invested" calculator: VRTX performance & returns.

What is the best month to buy VRTX?

The 12 months ranked by the stock's past returns: best & worst month to buy VRTX.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)